Novacta strengthens leadership team
This article was originally published in Scrip
Novacta Therapeutics, a privately held UK anti-infective biotechnology company, has appointed Dr David Pompliano non-executive director. He will also provide strategic direction to the company's R&D team and will serve as chairman of the scientific advisory board. Dr Pompliano was formerly vice-president and worldwide basic research head of antimicrobials at Merck & Co.
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.